Stewart GD, Klatte T, Cosmai L, Bex A, Lamb BW, Moch H, Sala E, Siva S, Porta C, Gallieni M (2022) The multispeciality approach to the management of localised kidney cancer. Lancet 400:523–534. https://doi.org/10.1016/S0140-6736(22)01059-5
Alaghehbandan R, Perez Montiel D, Luis AS, Hes O (2019) Molecular genetics of renal cell tumors: a practical diagnostic approach. Cancers (Basel) 12. https://doi.org/10.3390/cancers12010085
Moch H, Amin MB, Berney DM, Comperat EM, Gill AJ, Hartmann A, Menon S, Raspollini MR, Rubin MA, Srigley JR, Hoon Tan P, Tickoo SK, Tsuzuki T, Turajlic S, Cree I, Netto GJ (2022) The 2022 World Health Organization Classification of tumours of the urinary system and male genital organs-part A: renal, penile, and testicular tumours. Eur Urol 82:458–468. https://doi.org/10.1016/j.eururo.2022.06.016
Al-Obaidy KI, Eble JN, Nassiri M, Cheng L, Eldomery MK, Williamson SR, Sakr WA, Gupta N, Hassan O, Idrees MT, Grignon DJ (2020) Recurrent KRAS mutations in papillary renal neoplasm with reverse polarity. Mod Pathol 33:1157–1164. https://doi.org/10.1038/s41379-019-0362-1
Article CAS PubMed Google Scholar
Argani P, Reuter VE, Eble JN, Vlatkovic L, Yaskiv O, Swanson D, Dickson BC, Antonescu CR, Matoso A, Gagan J, Palsgrove DN (2020) Biphasic hyalinizing psammomatous renal cell carcinoma (BHP RCC): a distinctive neoplasm associated with somatic NF2 mutations. Am J Surg Pathol 44:901–916. https://doi.org/10.1097/PAS.0000000000001467
Article PubMed PubMed Central Google Scholar
Farcas M, Gatalica Z, Trpkov K, Swensen J, Zhou M, Alaghehbandan R, Williamson SR, Magi-Galluzzi C, Gill AJ, Tretiakova M, Lopez JI, Montiel DP, Sperga M, Comperat E, Brimo F, Yilmaz A, Siadat F, Sangoi A, Gao Y, Ptakova N, Kuthi L, Pivovarcikova K, Rogala J, Agaimy A, Hartmann A, Fraune C, Rychly B, Hurnik P, Durcansky D, Bonert M, Gakis G, Michal M, Hora M, Hes O (2022) Eosinophilic vacuolated tumor (EVT) of kidney demonstrates sporadic TSC/MTOR mutations: next-generation sequencing multi-institutional study of 19 cases. Mod Pathol 35:344–351. https://doi.org/10.1038/s41379-021-00923-6
Article CAS PubMed Google Scholar
Williamson SR, Hes O, Trpkov K, Aggarwal A, Satapathy A, Mishra S, Sharma S, Sangoi A, Cheng L, Akgul M, Idrees M, Levin A, Sadasivan S, San Miguel Fraile P, Rogala J, Comperat E, Berney DM, Bulimbasic S, McKenney JK, Jha S, Sampat NY, Mohanty SK (2023) Low-grade oncocytic tumour of the kidney is characterised by genetic alterations of TSC1, TSC2, MTOR or PIK3CA and consistent GATA3 positivity Histopathology 82:296–304. https://doi.org/10.1111/his.14816
Al-Obaidy KI, Bridge JA, Cheng L, Sumegi J, Reuter VE, Benayed R, Hameed M, Williamson SR, Hes O, Alruwaii FI, Segal JP, Wanjari P, Idrees MT, Nassiri M, Eble JN, Grignon DJ (2021) EWSR1-PATZ1 fusion renal cell carcinoma: a recurrent gene fusion characterizing thyroid-like follicular renal cell carcinoma. Mod Pathol 34:1921–1934. https://doi.org/10.1038/s41379-021-00833-7
Article CAS PubMed Google Scholar
Ricketts CJ, De Cubas AA, Fan H, Smith CC, Lang M, Reznik E, Bowlby R, Gibb EA, Akbani R, Beroukhim R, Bottaro DP, Choueiri TK, Gibbs RA, Godwin AK, Haake S, Hakimi AA, Henske EP, Hsieh JJ, Ho TH, Kanchi RS, Krishnan B, Kwiatkowski DJ, Lui W, Merino MJ, Mills GB, Myers J, Nickerson ML, Reuter VE, Schmidt LS, Shelley CS, Shen H, Shuch B, Signoretti S, Srinivasan R, Tamboli P, Thomas G, Vincent BG, Vocke CD, Wheeler DA, Yang L, Kim WY, Robertson AG, Spellman PT, Rathmell WK, Linehan WM (2018) The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma. Cell Reports 23:313-326.e315. https://doi.org/10.1016/j.celrep.2018.03.075
Article CAS PubMed Google Scholar
Davis CF, Ricketts CJ, Wang M, Yang L, Cherniack AD, Shen H, Buhay C, Kang H, Kim SC, Fahey CC, Hacker KE, Bhanot G, Gordenin DA, Chu A, Gunaratne PH, Biehl M, Seth S, Kaipparettu BA, Bristow CA, Donehower LA, Wallen EM, Smith AB, Tickoo SK, Tamboli P, Reuter V, Schmidt LS, Hsieh JJ, Choueiri TK, Hakimi AA, The Cancer Genome Atlas Research N, Chin L, Meyerson M, Kucherlapati R, Park WY, Robertson AG, Laird PW, Henske EP, Kwiatkowski DJ, Park PJ, Morgan M, Shuch B, Muzny D, Wheeler DA, Linehan WM, Gibbs RA, Rathmell WK, Creighton CJ (2014) The somatic genomic landscape of chromophobe renal cell carcinoma Cancer Cell 26:319-330. https://doi.org/10.1016/j.ccr.2014.07.014
Sun G, Zhang X, Liang J, Pan X, Zhu S, Liu Z, Armstrong CM, Chen J, Lin W, Liao B, Lin T, Huang R, Zhang M, Zheng L, Yin X, Nie L, Shen P, Zhao J, Zhang H, Dai J, Shen Y, Li Z, Liu J, Chen J, Liu J, Wang Z, Zhu X, Ni Y, Qin D, Yang L, Chen Y, Wei Q, Li X, Zhou Q, Huang H, Yao J, Chen N, Zeng H (2021) Integrated molecular characterization of fumarate hydratase-deficient renal cell carcinoma. Clin Cancer Res 27:1734–1743. https://doi.org/10.1158/1078-0432.CCR-20-3788
Article CAS PubMed Google Scholar
Board WCotE (2022) Classification of tumours of the urinary system and male genital organs. ed. 5 Lyon, France: International Agency for Research on Cancer
Lawrie CH, Armesto M, Fernandez-Mercado M, Arestin M, Manterola L, Goicoechea I, Larrea E, Caffarel MM, Araujo AM, Sole C, Sperga M, Alvarado-Cabrero I, Michal M, Hes O, Lopez JI (2018) Noncoding RNA expression and targeted next-generation sequencing distinguish tubulocystic renal cell carcinoma (TC-RCC) from other renal neoplasms. J Mol Diagn : JMD 20:34–45. https://doi.org/10.1016/j.jmoldx.2017.09.002
Article CAS PubMed Google Scholar
Becker F, Junker K, Parr M, Hartmann A, Fussel S, Toma M, Grobholz R, Pflugmann T, Wullich B, Strauss A, Behnes CL, Otto W, Stockle M, Jung V (2013) Collecting duct carcinomas represent a unique tumor entity based on genetic alterations. PLoS ONE 8:e78137. https://doi.org/10.1371/journal.pone.0078137
Article CAS PubMed PubMed Central Google Scholar
Wang J, Papanicolau-Sengos A, Chintala S, Wei L, Liu B, Hu Q, Miles KM, Conroy JM, Glenn ST, Costantini M, Magi-Galluzzi C, Signoretti S, Choueiri T, Gallucci M, Sentinelli S, Fazio VM, Poeta ML, Liu S, Morrison C, Pili R (2016) Collecting duct carcinoma of the kidney is associated with CDKN2A deletion and SLC family gene up-regulation. Oncotarget 7:29901–29915. https://doi.org/10.18632/oncotarget.9093
Trpkov K, Hes O, Agaimy A, Bonert M, Martinek P, Magi-Galluzzi C, Kristiansen G, Lüders C, Nesi G, Compérat E, Sibony M, Berney DM, Mehra R, Brimo F, Hartmann A, Husain A, Frizzell N, Hills K, Maclean F, Srinivasan B, Gill AJ (2016) Fumarate hydratase-deficient renal cell carcinoma is strongly correlated with fumarate hydratase mutation and hereditary leiomyomatosis and renal cell carcinoma syndrome. Am J Surg Pathol 40:865–875. https://doi.org/10.1097/PAS.0000000000000617
Kuroda N, Tsutsui M, Iguchi M, Nobuoka E, Uehara T, Sonobe Y, Morinaga Y, Shibuya S, Oda W, Yanai H, Kawada C, Karashima T, Yamasaki I, Inoue K, Nagashima Y (2020) Fumarate hydratase-deficient renal cell carcinoma: a clinicopathological study of seven cases including hereditary and sporadic forms. Ann Diagn Pathol 49:151599. https://doi.org/10.1016/j.anndiagpath.2020.151599
Lu E, Hatchell KE, Nielsen SM, Esplin ED, Ouyang K, Nykamp K, Zavoshi S, Li S, Zhang L, Wilde BR, Christofk HR, Boutros PC, Shuch B (2022) Fumarate hydratase variant prevalence and manifestations among individuals receiving germline testing. Cancer 128:675–684. https://doi.org/10.1002/cncr.33997
Article CAS PubMed Google Scholar
Wyvekens N, Valtcheva N, Mischo A, Helmchen B, Hermanns T, Choschzick M, Hotker AM, Rauch A, Muhleisen B, Akhoundova D, Weber A, Moch H, Rupp NJ (2020) Novel morphological and genetic features of fumarate hydratase deficient renal cell carcinoma in HLRCC syndrome patients with a tailored therapeutic approach. Genes Chromosomes Cancer 59:611–619. https://doi.org/10.1002/gcc.22878
Article CAS PubMed Google Scholar
Hamza A, Sirohi D, Smith SC, Amin MB (2021) Low-grade oncocytic fumarate hydratase-deficient renal cell carcinoma: an update on biologic potential, morphologic spectrum, and differential diagnosis with other low-grade oncocytic tumors. Adv Anat Pathol 28:396–407. https://doi.org/10.1097/PAP.0000000000000321
Article CAS PubMed Google Scholar
Mannan R, Wang X, Bawa PS, Chugh S, Chinnaiyan AK, Rangaswamy R, Zhang Y, Cao X, Smith SC, Trpkov K, Williamson SR, Sangoi AR, Mohanty S, McKenney JK, Gupta S, Magi-Galluzzi C, Argani P, Osunkoya AO, Chinnaiyan AM, Dhanasekaran SM, Mehra R (2023) Characterization of protein S-(2-succino)-cysteine (2SC) succination as a biomarker for fumarate hydratase-deficient renal cell carcinoma. Hum Pathol 134:102–113. https://doi.org/10.1016/j.humpath.2022.12.013
Article CAS PubMed Google Scholar
Zheng LM, Zhang XM, Pan XY, Zhou Q, Zeng H, Chen N (2023) AKR1B10 is a new sensitive and specific marker for fumarate hydratase-deficient renal cell carcinoma. Lab Invest 103:S840–S841
Lau HD, Chan E, Fan AC, Kunder CA, Williamson SR, Zhou M, Idrees MT, Maclean FM, Gill AJ, Kao CS (2020) A clinicopathologic and molecular analysis of fumarate hydratase-deficient renal cell carcinoma in 32 patients. Am J Surg Pathol 44:98–110. https://doi.org/10.1097/PAS.0000000000001372
Gill AJ (2018) Succinate dehydrogenase (SDH)-deficient neoplasia. Histopathology 72:106–116. https://doi.org/10.1111/his.13277
Tsai TH, Lee WY (2019) Succinate dehydrogenase-deficient renal cell carcinoma. Arch Pathol Lab Med 143:643–647. https://doi.org/10.5858/arpa.2018-0024-RS
Article CAS PubMed Google Scholar
Brunelli M, Delahunt B, Gobbo S, Tardanico R, Eccher A, Bersani S, Cossu-Rocca P, Parolini C, Balzarini P, Menestrina F, Cheng L, Eble JN, Martignoni G (2010) Diagnostic usefulness of fluorescent cytogenetics in differentiating chromophobe renal cell carcinoma from renal oncocytoma: a validation study combining metaphase and interphase analyses. Am J Clin Pathol 133:116–126. https://doi.org/10.1309/AJCPSATJTKBI6J4N
Lichner Z, Scorilas A, White NM, Girgis AH, Rotstein L, Wiegand KC, Latif A, Chow C, Huntsman D, Yousef GM (2013) The chromatin remodeling gene ARID1A is a new prognostic marker in clear cell renal cell carcinoma. Am J Pathol 182:1163–1170. https://doi.org/10.1016/j.ajpath.2013.01.007
Article CAS PubMed Google Scholar
Grundy PE, Breslow NE, Li S, Perlman E, Beckwith JB, Ritchey ML, Shamberger RC, Haase GM, D’Angio GJ, Donaldson M, Coppes MJ, Malogolowkin M, Shearer P, Thomas PR, Macklis R, Tomlinson G, Huff V, Green DM, National Wilms Tumor Study G (2005) Loss of heterozygosity for chromosomes 1p and 16q is an adverse prognostic factor in favorable-histology Wilms tumor: a report from the National Wilms Tumor Study Group. J Clin Oncol 23:7312–7321. https://doi.org/10.1200/JCO.2005.01.2799
Article CAS PubMed Google Scholar
Chagtai T, Zill C, Dainese L, Wegert J, Savola S, Popov S, Mifsud W, Vujanic G, Sebire N, Le Bouc Y, Ambros PF, Kager L, O’Sullivan MJ, Blaise A, Bergeron C, Mengelbier LH, Gisselsson D, Kool M, Tytgat GA, van den Heuvel-Eibrink MM, Graf N, van Tinteren H, Coulomb A, Gessler M, Williams RD, Pritchard-Jones K (2016) Gain of 1q as a prognostic biomarker in Wilms tumors (WTs) treated with preoperative chemotherapy in the International Society of Paediatric Oncology (SIOP) WT 2001 Trial: A SIOP Renal Tumours Biology Consortium Study. J Clin Oncol 34:3195–3203. https://doi.org/10.1200/JCO.2015.66.0001
Article CAS PubMed PubMed Central Google Scholar
Gratias EJ, Dome JS, Jennings LJ, Chi YY, Tian J, Anderson J, Grundy P, Mullen EA, Geller JI, Fernandez CV, Perlman EJ (2016) Association of chromosome 1q gain with inferior survival in favorable-histology Wilms tumor: a report from the Children’s Oncology Group. J Clin Oncol 34:3189–3194. https://doi.org/10.1200/JCO.2015.66.1140
Article PubMed PubMed Central Google Scholar
Zheng J (2013) Oncogenic chromosomal translocations and human cancer (review). Oncol Rep 30:2011–2019. https://doi.org/10.3892/or.2013.2677
Article CAS PubMed Google Scholar
Kuroda N, Trpkov K, Gao Y, Tretiakova M, Liu YJ, Ulamec M, Takeuchi K, Agaimy A, Przybycin C, Magi-Galluzzi C, Fushimi S, Kojima F, Sibony M, Hang JF, Pan CC, Yilmaz A, Siadat F, Sugawara E, Just PA, Ptakova N, Hes O (2020) ALK rearranged renal cell carcinoma (ALK-RCC): a multi-institutional study of twelve cases with identification of novel partner genes CLIP1, KIF5B and KIAA1217. Mod Pathol 33:2564–2579. https://d
Comments (0)